S&P Futures
4,004.75 -15.00 (-0.37%) Dow Futures
32,070.00 -50.00 (-0.16%) Nasdaq Futures
12,305.25 -77.50 (-0.63%) Russell 2000 Futures
1,782.20 -7.30 (-0.41%) Crude Oil
109.95 -0.54 (-0.49%) Gold
1,798.70 -9.50 (-0.53%)
Synthetic Biologics, Inc. (SYN)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 0.2000 |
| Open | 0.2100 |
| Bid | 0.2150 x 800 |
| Ask | 0.2200 x 800 |
| Day's Range | 0.2092 - 0.2315 |
| 52 Week Range | 0.2000 - 0.7200 |
| Volume | |
| Avg. Volume | 2,948,698 |
| Market Cap | 30.238M |
| Beta (5Y Monthly) | 1.68 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.2240 |
| Earnings Date | Mar 02, 2022 - Mar 07, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Benzinga
Synthetic Biologics Posts Encouraging Safety Data on SYN-020 In Healthy Volunteers
Synthetic Biologics Inc (NYSE: SYN) has announced safety data from its Phase 1 multiple ascending dose (MAD) trial of SYN-020 intestinal alkaline phosphatase (IAP). The Phase 1 MAD study enrolled 32 healthy adult volunteers into four cohorts with SYN-020 administered orally in doses ranging from 5 mg to 75 mg twice daily for 14 days, with a follow-up evaluation at day 35. SYN-020 is a recombinant bovine IAP formulated for oral delivery to the small intestine and designed to diminish fat absorpti
- GlobeNewswire
Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial
-Orally administered SYN-020 observed to be well tolerated across all doses in healthy volunteers- ROCKVILLE, Md., May 10, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced positive safety data from its Phase 1, placebo-controlled, double-blind multiple ascending dose (MAD) clinical trial of SYN-020 intestinal alkaline phosphatase (IAP). The
- GlobeNewswire
Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results
ROCKVILLE, Md., May 09, 2022 (GLOBE NEWSWIRE) -- Synthetic Biologics, Inc. (NYSE American: SYN), a diversified clinical-stage company developing therapeutics designed to treat diseases in areas of high unmet need, today announced that it plans to host a conference call on Monday, May 16, 2022, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a corporate update. Individuals may participate in the live call via telephone by dialing (877) 451-6152 (d
